| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Comprehensive cancer care starts with MayoComplete
At Mayo Clinic, we recognize that multiple factors, such as history, diagnosis, specimen availability, and prognosis, affect which test a patient receives. Understanding the unique genetic features of patients' tumors is essential to helping physicians select from an array of treatment options to devise an optimal care plan for each patient. Comprehensive genetic testing is the first step in starting cancer patients down the right path.
Our full menu of MayoComplete solid tumor testing includes a comprehensive, 515-gene panel and multiple disease-specific panels, which span the cancer spectrum. Using next-generation sequencing, our MayoComplete testing ensures each patient receives personalized answers to guide their care.
Learn more about our full suite of MayoComplete next-generation sequencing panels for hematologic and oncologic conditions.
Cancer specimens can be small and can vary in tumor content. Obtaining enough tissue for multiple molecular and histological tests has historically created a significant challenge for pathologists in testing patients for clinically actionable mutations as recommended. We have optimized specimen requirements by reducing the amount of FFPE tissue and accepting cytology as an alternative specimen type, which allows more patients to receive results.
MayoComplete Next-Generation Sequencing: Oncology Subpanels
In this "Hot Topic," Kevin Halling, M.D., Ph.D., discusses new next generation sequencing testing for various tumor types and the rationale for the enhancements that were made; reviews gene additions that are now available in each of the panels; and briefly speaks about the work that was done to validate cytology specimens for use in the subpanels.
Because testing is complex and selecting the right assay can be challenging, our team of board-certified geneticists and genetic counselors is available to assist with questions related to testing options and results interpretation. MayoComplete solid tumor testing includes detailed reports that highlight diagnostic findings, therapeutic associations, availability of on- and off-label therapies, prognostic markers, and existence of applicable clinical trials that enable deeper understanding of the best treatment courses.
